Brief: AB Science Receives Second Authorisation To Resume Enrollment In Phase 3 Study Of Masitinib in Mastocytosis
25/08/2021 17:52
Aug 25 (Reuters) - AB SCIENCE SA ABS.PA :
* ANNOUNCES THAT IT HAS RECEIVED A SECOND AUTHORIZATION TO
RESUME
PATIENT ENROLLMENT, IN THE PHASE 3 STUDY OF MASITINIB IN
MASTOCYTOSIS
* EXPECTS TO BE ABLE TO PROGRESSIVELY RESUME GLOBAL PATIENT
ENROLLMENT IN MASTOCYTOSIS STUDY DURING MONTH OF SEPTEMBER
* THIS TEMPORARY INTERRUPTION DOES NOT MODIFY RECRUITMENT
SCHEDULE, WITH RECRUITMENT COMPLETION EXPECTED IN 2022 FOR THIS
CONFIRMATORY STUDY, AS INITIALLY PLANNED
Source text for Eikon: ID:nGNE1KFbQV
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease